This site is intended for health professionals only

FDA passes Strides’ heart drug


Strides Arcolab has received FDA approval for its heart attack drug Metoprolol Tartrate.

The company said the treatment would be marketed in latex-free 5mg per 5ml vials.

Metoprolol is the sixth product launched as part of the partnership between Strides and Sagent Pharmaceuticals – a deal that sees the former develop and supply injectable products while Sargent concentrates on marketing efforts.

Article continues below this sponsored advert
Cogora InRead Image
Join us at a one-day virtual cardiology event that will allow you to explore the latest advances in cardiovascular care. With the help of an advisory board of cardiology specialists we have put together an agenda tailored to multi-disciplinary teams - each talk is presented by an expert, or panel, who will share knowledge and case studies of relevance

Mr Ravi Seth, chief executive officer of international operations at Strides, said: “We are delighted with the receipt of the third product approval from the USFDA within 10 days which reflects the strong development capabilities of Strides.

“This is an important addition to cardiovascular care portfolio of the partnership with Sagent, which already includes Adenosine vials and Labetalol vials, and has received seven approvals till date.”

Copyright Press Association 2010
Strides Arcolab

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine